Chief Medical Officer Summit 2018
NEW TO 2018. This inaugural event, will define and address the unique challenges associated with managing Medical Affairs functions with limited resources.
The summit aims to enable CMO and R+D executives to understand possible routes for raising capital, partner with big Pharma, address and support the skills required to be a CMO in a SME and create a network to share ideas, solutions and support.
Regulatory considerations around innovation support, clinical trials and Brexit will also be debated.
Monday 5 March 2018
Wellcome Collection
183 Euston Road
London
NW1 2BE
UK
08:45 - 09:30 Registration, refreshments and networking
09:30 - 09:45 Welcome and scene setting
Steve Bates OBE, Chief Executive Officer, BioIndustry Association
09:45 - 10:05 Opening keynote address
Louise Wood, NIHR
10:05 - 11:00 The role of a Chief Medical Officer
The role of Chief Medical Officer (CMO) is evolving in response to the requirement for biotechnology and pharmaceutical companies to apply more ethical and scientific rigor to decision making, driven by both the public and the broader medical community. This session will explore this changing role from the point of view of the ‘Investor’, the ‘Regulator’ and the CMO him/herself.
Chairperson: Glen Clack, Honorary Professor of Translational Medicine, Department of Oncology and Metabolism, University of Sheffield
Panel and presentations
- View from Investors – Hamish Cameron, SV Health Investors
- View from a regulatory perspective – David Jefferys, Eisai
- View from the coalface – Dr Penny Ward, Chief Medical Officer, Karus Therapeutics
11:00 - 11:30 Refreshments and networking
11:30 - 13:00 Essential skills
Effective Chief Medical Officers require a wide and varied skillset, resilience and adaptability. This session addresses methods to assist the acquisition, maintenance and improvement of skills to remain effective within the continuously evolving pharmaceutical environment.
Chairperson: Professor Alan Boyd, President, Faculty of Pharmaceutical Medicine
Panel Members
- Dr Ian Mills
- Dr Mike Perkins
- Dr Kevin Bryett
Presentations on Postgraduate Training in Pharmaceutical Medicine and Revalidation followed by a Panel Discussion
13:00– 14:00 Lunch and networking
14:00 – 15:30 Regulatory considerations around innovation support, clinical trials and Brexit
This session will highlight the strength of the UK regulatory system, supporting innovation through the MHRA Innovation Office and Early Access to Medicines Scheme (EAMS). New EU clinical trials regulations and the implications of Brexit will also be discussed.
Chairperson: Steve Bates OBE, CEO, BioIndustry Association
Presentations and panel
MHRA support to innovation
- Innovation Office – Ian Rees, MHRA
- EAMS - Daniel O’Connor, MHRA
- Funding for SMEs in EAMS – Ian Campbell, Director of Health & Life Sciences, IUK
Clinical trials regulation – Kirsty Wydenbach, MHRA
- Revised EMA guideline on first-in-human clinical trials
- New EU Clinical Trials Regulation
- Brexit
15:30 - 16:00 Refreshments and networking
16:00 - 17:30 Partnering with Pharma and NHS
Finding and fostering effective partnerships is an essential element of life in a biotech company. This session explores ways to support effective partnering across the variety of situations likely to be encountered in the life of a biotech CMO.
Chairperson: Dr Penny Ward, Chief Medical Officer, Karus Therapeutics
Presentations and panel
- Renata Crome, Cancer Research UK
- Matthew Hallsworth, NIHR NOCRI
- Dr Patrick Round, Consultant
- Jonathan van Tam, NHS England
17:30 - 17:40 Summary and close
17:40 - 19:00 Drinks and networking
Academic/NHS/NFP - £195.00
FPM members - £425.00
BIA members - £425.00
Non members - £575.00
(Above fees exclude VAT)